Top 10 Stocks To Own For 2018

&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-1060141868&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1060141868/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Shutterstock

With just over a week to go until&a;nbsp;Tax Day (it&s;s&a;nbsp;&l;a href=&q;https://www.forbes.com/sites/kellyphillipserb/2018/01/04/irs-announces-2018-filing-season-opens-january-29-reminds-taxpayers-about-delayed-refunds/#587ab89410da&q;&g;April 17 this year&l;/a&g;), you have a few options available if you still haven&s;t yet filed your tax return. You can:

&l;/p&g;&l;ul&g;&l;li&g;Call and hope to get a last-minute tax appointment;&l;/li&g;

&l;li&g;Download tax prep software and figure you&s;ll squeeze the time to file while binge-watching &l;em&g;Stranger Things&l;/em&g;;&l;/li&g;

&l;li&g;Rock back and forth quietly under your desk while promising to be more prepared next year; or&l;/li&g;

&l;li&g;You can join the nearly 10 million taxpayers who are expected to file for an extension.&l;/li&g;

Top 10 Stocks To Own For 2018: Exelon Corporation(EXC)

Advisors’ Opinion:

  • [By Horizon Investments]

    For the past year, Exelon Corp. (EXC) has had a roller coaster ride, with the stock having plummeted 15% since September 2012 – the company had announced a dividend cut of 41%, which led to a drop in the share price. Separately, the recent weak PJM auction prices did not bode well for the company. However, I believe the worst is priced in the stock price, and the company’s management is committed to improving its financial flexibility and cost structure in order to strengthen its financial performance. Also, the company is planning to incur capital expenditure (CAPEX) in the upcoming years, which will result in rate base growth for Exelon.

  • [By Monica Gerson]

    Exelon Corporation (NYSE: EXC) is expected to report its quarterly earnings at $0.68 per share on revenue of $7.52 billion.

    CST Brands Inc (NYSE: CST) is projected to report its quarterly earnings at $0.22 per share on revenue of $2.30 billion.

  • [By Casey Wilson]

    That brings us to General Electric Co. (NYSE: GE). The 125-year-old American mainstay signed a deal with Exelon Corp. (NYSE: EXC) last fall for the energy utility to use its own predictive analytics software, fittingly dubbed “Predix.”

Top 10 Stocks To Own For 2018: PAR Technology Corporation(PAR)

Advisors’ Opinion:

  • [By Lisa Levin]

    PAR Technology Corporation (NYSE: PAR) shares were also up, gaining 15 percent to $6.59. Par Technology reported Q4 adjusted earnings of $0.13 per share on revenue of $56.8 million.

  • [By Lisa Levin]

    On Tuesday, technology shares gained by 1.61 percent. Meanwhile, top gainers in the sector included Himax Technologies, Inc. (ADR) (NASDAQ: HIMX), up 13 percent, and PAR Technology Corporation (NYSE: PAR), up 9 percent.

Top 10 Stocks To Own For 2018: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Gilead Sciences have dipped 0.1% to $68.97 at 1:05 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $296.51.

  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

  • [By Ben Levisohn]

    Biotech stocks are having a great day today–iShares Nasdaq Biotechnology ETF (IBB) has climbed 2.5% to $276.92–leading some to suggest that 2017 could be better for investors than 2016 was. Not Baird’s Brian Skorney and Michael Ulz, who “don’t think 2017 will be worse than 2016″ but “aren’t quite sure it will be much better.” They explain why:

    Agence France-Presse/Getty Images

    Short story is, growth products are slowing and large net price increases are appearing increasingly unsustainable, even if the government doesn’t intervene. The innovation cycle appears to be in a waning period and, so far, large-caps with boatloads of cash seem to be hesitant to act. 2017 should have some excitement. We may finally see a successful registrational study in Alzheimer’s disease (Axovant Sciences’ (AXON) intepirdine or Merck’s (MRK) verubecestat), CAR T will finally get to plead its case, and we may find out once and for all if those ‘transformational’ PCSK9s are just that…

    A steadily building pharma cash war chest is a big offsetting tailwind. As Princess Leia would say, “Help me M&A, you’re my only hope.”

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

Top 10 Stocks To Own For 2018: CytRx Corporation(CYTR)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.

    If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.

    Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.

    Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Stocks To Own For 2018: Castlight Health, inc.(CSLT)

Advisors’ Opinion:

  • [By Todd Campbell]

    Castlight Health (NYSE:CSLT)share price climbed 13.2% Wednesday after an SEC filing revealed that Maverick Capital had significantly boosted its stake in the company to 10.6%.

Top 10 Stocks To Own For 2018: Western Asset Mortgage Capital Corporation(WMC)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine lowered shares of Western Asset Mortgage Capit (NYSE:WMC) from a buy rating to a hold rating in a research report report published on Wednesday.

Top 10 Stocks To Own For 2018: SPDR Wells Fargo Preferred Stock ETF (PSK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI holds five other SSgA fixed income ETFs, including the SPDR Wells Fargo Preferred Stock ETF (NYSE: PSK). PSK is DWFI's largest holding at a weight of 25.2 percent. DWFI's second-largest holding is an allocation of almost 25 percent to the SPDR Nuveen Barclays Municipal Bond ETF (NYSE: TFI).

Top 10 Stocks To Own For 2018: comScore Inc.(SCOR)

Advisors’ Opinion:

  • [By Paul Ausick]

    comScore Inc. (NASDAQ: SCOR) dropped more than 10% on Tuesday to record a new 52-week low of $20.81. The stock closed at $23.22 on Monday. Volume was about 9 times the daily average of around 470,000 shares. The company’s stock will be de-listed from Nasdaq effective February 8 unless the company receives a stay from the exchange.

Top 10 Stocks To Own For 2018: Caladrius Biosciences, Inc.(CLBS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Caladrius Biosciences Inc (NASDAQ: CLBS) shares shot up 14 percent to $5.83 after the company posted upbeat Q4 results.

    Shares of Norsat International Inc (USA) (NYSE: NSAT) got a boost, shooting up 22 percent to $9.85 after the company reported the receipt of new indication of interest by Privet Fund Management LLP at $10.25 per share.

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Caladrius Biosciences Inc. (NASDAQ: CLBS) watchedits shares soar on Thursday after the company announced a private placement offering. In terms of the specifics, the company entered into securities purchase agreements with several accredited investors for the sale of 4,449,153 shares of its common stock in private placements of $21 million.

Top 10 Stocks To Own For 2018: News Corporation(NWS)

Advisors’ Opinion:

  • [By Monica Gerson]

    News Corp (NASDAQ: NWS) reported a profit of $506 million, or $0.87 per share for the year ended June 30, versus a year-ago loss of $2.08 billion, or $3.58 per share. Its revenue rose 2.7% to $8.89 billion. However, analysts were expecting earnings of $0.57 per share on revenue of $8.96 billion. News Corp shares fell 1.28% to close at $16.91 on Friday.

  • [By Joseph Griffin]

    New Media Inv Group (NYSE: NEWM) and News (NASDAQ:NWS) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Leave a Reply

Your email address will not be published. Required fields are marked *